| Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States TW Rice, L Rubinson, TM Uyeki, FL Vaughn, BB John, RR Miller III, ... Critical care medicine 40 (5), 1487-1498, 2012 | 430 | 2012 |
| Critically ill children during the 2009–2010 influenza pandemic in the United States AG Randolph, F Vaughn, R Sullivan, L Rubinson, BT Thompson, G Yoon, ... Pediatrics 128 (6), e1450-e1458, 2011 | 233 | 2011 |
| Geographic inequity in access to livers for transplantation H Yeh, E Smoot, DA Schoenfeld, JF Markmann Transplantation 91 (4), 479-486, 2011 | 177 | 2011 |
| Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study M Trauner, F Nevens, ML Shiffman, JPH Drenth, CL Bowlus, V Vargas, ... The Lancet Gastroenterology & Hepatology 4 (6), 445-453, 2019 | 157 | 2019 |
| The value of positive end-expiratory pressure and Fio2 criteria in the definition of the acute respiratory distress syndrome M Britos, E Smoot, KD Liu, BT Thompson, W Checkley, RG Brower, ... Critical care medicine 39 (9), 2025-2030, 2011 | 106 | 2011 |
| A prospective, randomized comparison of bovine carotid artery and expanded polytetrafluoroethylene for permanent hemodialysis vascular access PT Kennealey, N Elias, M Hertl, DSC Ko, RF Saidi, JF Markmann, ... Journal of vascular surgery 53 (6), 1640-1648, 2011 | 83 | 2011 |
| Pediatric acute lung injury and sepsis investigator’s network and the national heart, lung, and blood institute ARDS Clinical Trials Network. Critically ill children during the … AG Randolph, F Vaughn, R Sullivan, L Rubinson, BT Thompson, G Yoon, ... Pediatrics 128 (6), e1450-e1458, 2011 | 55 | 2011 |
| Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis M Van Blitterswijk, S Gulati, E Smoot, M Jaffa, N Maher, BT Hyman, ... Amyotrophic lateral sclerosis 12 (6), 430-438, 2011 | 43 | 2011 |
| Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls CFM Perez, H Fisher, S Hiu, D Kareithi, F Adekunle, T Mayne, E Malecha, ... Gastroenterology 163 (6), 1630-1642. e3, 2022 | 37 | 2022 |
| HCC patients suffer less from geographic differences in organ availability C Schuetz, N Dong, E Smoot, N Elias, DA Schoenfeld, JF Markmann, ... American Journal of Transplantation 13 (11), 2989-2995, 2013 | 26 | 2013 |
| Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis A Parés, M Shiffman, V Vargas, P Invernizzi, ES Malecha, A Liberman, ... Liver International 40 (5), 1121-1129, 2020 | 21 | 2020 |
| Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis MH Harms, GM Hirschfield, A Floreani, MJ Mayo, A Parés, A Liberman, ... JHEP Reports 3 (1), 100191, 2021 | 17 | 2021 |
| On the analysis of hybrid designs that combine group‐and individual‐level data E Smoot, S Haneuse Biometrics 71 (1), 227-236, 2015 | 12 | 2015 |
| National Institutes of Health Acute Respiratory Distress Syndrome Network I. The value of positive end-expiratory pressure and Fio (2) criteria in the definition of the acute … M Britos, E Smoot, KD Liu, BT Thompson, W Checkley, RG Brower Crit Care Med 39 (9), 2025-2030, 2011 | 11 | 2011 |
| Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis F Nevens, ML Shiffman, JPH Drenth, CL Bowlus, V Vargas, P Andreone, ... Digestive and Liver Disease 52, e30, 2020 | 9 | 2020 |
| Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC) C Bowlus, P Pockros, AE Kremer, A Pares, L Forman, JP Drenth, S Ryder, ... Journal of Hepatology 68, S111-S112, 2018 | 7 | 2018 |
| Omega-3 (n-3) fatty acid, gamma-linolenic acid (GLA) and anti-oxidant supplementation in acute lung injury (OMEGA trial) T Rice, B Thompson, E Smoot, A Wheeler Critical Care Medicine 37 (12), A408-A408, 2009 | 7 | 2009 |
| Durable response in the markers of cholestasis through 36 months of open label extension study of obeticholic acid in primary biliary cholangitis F Nevens Journal of Hepatology 68 (6), S224-S225, 2018 | 6 | 2018 |
| Long-term efficacy and safety of obeticholic acid in patients with PBC from the POISE trial grouped biochemically by risk of disease progression CL Bowlus, MH Trauner, AE Kremer, A Liberman, ES Malecha, ... Hepatology 72, 751A-752A, 2020 | 4 | 2020 |
| Patients with primary biliary cholangitis treated with long-term obeticholic acid in a trial-setting demonstrate better transplant-free survival than external controls from the … CFM Perez, H Fisher, S Hiu, F Adekunle, M Bonacci, T Mayne, ... AASLD The liver meeting 74 (6), 1389A-1390A, 2021 | 3 | 2021 |
